Cargando…

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable new treatment option for patients with B-cell malignancies. However, by applying selective pressure, outgrowth of antigen-negative tumor cells can occur, eventually resulting in relapse. Subsequent rescue by admin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roex, Gils, Campillo-Davo, Diana, Flumens, Donovan, Shaw, Philip Anthony Gilbert, Krekelbergh, Laurens, De Reu, Hans, Berneman, Zwi N., Lion, Eva, Anguille, Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919645/ https://www.ncbi.nlm.nih.gov/pubmed/35287669 http://dx.doi.org/10.1186/s12967-022-03326-6

Ejemplares similares

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy
por: Campillo-Davo, Diana, et al.
Publicado: (2021)

One-step CRISPR-Cas9-mediated knockout of native TCRαβ genes in human T cells using RNA electroporation
por: Flumens, Donovan, et al.
Publicado: (2023)

Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
por: Campillo-Davo, Diana, et al.
Publicado: (2020)

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
por: Versteven, Maarten, et al.
Publicado: (2022)

In vitro expansion of Wilms’ tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells
por: van der Heijden, Sanne, et al.
Publicado: (2023)

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
por: Van Acker, Heleen H., et al.
Publicado: (2019)

The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses
por: Campillo-Davo, Diana, et al.
Publicado: (2020)

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
por: Ureña-Bailén, Guillermo, et al.
Publicado: (2022)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
por: Grote, Stefan, et al.
Publicado: (2020)

Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC
por: Lion, Eva, et al.
Publicado: (2011)

Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
por: Cutmore, Lauren C., et al.
Publicado: (2021)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia
por: Campillo-Davo, Diana, et al.
Publicado: (2021)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

CAR‐NK cells from engineered pluripotent stem cells: Off‐the‐shelf therapeutics for all patients
por: Lu, Shi‐Jiang, et al.
Publicado: (2021)

Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing
por: Campillo-Davo, Diana, et al.
Publicado: (2018)

Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner
por: Anguille, Sébastien, et al.
Publicado: (2015)

Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity
por: Van den Bergh, Johan, et al.
Publicado: (2015)

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
por: Caruso, Simona, et al.
Publicado: (2022)

Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion
por: Van Acker, Heleen H., et al.
Publicado: (2018)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells
por: Reichman, Avinoam, et al.
Publicado: (2022)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018)

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
por: Xiang, Jingyu, et al.
Publicado: (2023)

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
por: Versteven, Maarten, et al.
Publicado: (2018)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Interferon α may be back on track to treat acute myeloid leukemia
por: Smits, Evelien L.J.M., et al.
Publicado: (2013)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
por: Huang, Ruihao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3qkrtk130bht9ov4o2tbceja38